GlassScriptPhysician profile
Geetha N Varma
NPI 1740287978
$6,111.47
in general payments reported to CMS, 2019-2025
59 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $48.57 · 2021: $338 · 2022: $1,051 · 2023: $1,462 · 2024: $1,505 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,251 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,250.82 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $608.02 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $449.97 | 2021-2025 | Tagrisso, Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $431.07 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $390.26 | 2023-2024 | Precisetumor |
| Daiichi Sankyo INC. | $340.30 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $298.00 | 2021-2025 | |
| Astellas Pharma US INC | $280.98 | 2023-2025 | Xtandi, Xospata, Vyloy |
| Eisai INC. | $222.32 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $204.58 | 2021-2025 | Fotivda |
| Glaxosmithkline, LLC. | $174.10 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $157.05 | 2021-2025 | Trodelvy |
| Exelixis INC. | $128.20 | 2022-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $123.95 | 2019-2025 | Opdivo |
| Amgen INC. | $118.54 | 2019-2023 | Xgeva |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $98.82 | 2019-2025 | Orserdu |
| Beone Medicines USA, INC. | $97.82 | 2025 | Tevimbra |
| Springworks Therapeutics, INC. | $95.45 | 2024-2025 | Ogsiveo |
| Kite Pharma, INC. | $92.89 | 2021-2025 | Yescarta |
| Celgene Corporation | $91.79 | 2021-2024 | Pomalyst |
| Genentech USA, INC. | $91.34 | 2021-2025 | Polivy, Tecentriq, Itovebi |
| Abbvie INC. | $86.66 | 2022-2024 | |
| Taiho Oncology, INC. | $84.39 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.30 | 2024-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Lilly USA, LLC | $83.97 | 2022-2024 | Verzenio, Retevmo, Jaypirca |
| Seagen INC. | $82.58 | 2019-2022 | |
| Sobi, INC | $81.74 | 2022-2025 | |
| Pharmaessentia USA Corporation | $72.81 | 2023-2025 | Besremi |
| Emd Serono, INC. | $69.74 | 2021-2024 | |
| Rigel Pharmaceuticals, INC. | $59.63 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Regeneron Healthcare Solutions, INC. | $54.51 | 2023 | Libtayo |
| Servier Pharmaceuticals LLC | $45.71 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $44.43 | 2021-2022 | |
| Genzyme Corporation | $41.95 | 2021-2022 | |
| Kyowa Kirin, INC. | $40.16 | 2022 | |
| Jazz Pharmaceuticals INC. | $38.87 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.79 | 2023-2025 | |
| Sanofi US Services INC. | $37.99 | 2025 | |
| Beigene USA, INC. | $37.64 | 2022-2024 | Tevimbra |
| Incyte Corporation | $36.63 | 2022-2025 | Jakafi, Niktimvo |
| Merck Sharp & Dohme LLC | $33.83 | 2024 | Keytruda |
| Adc Therapeutics America, INC. | $32.54 | 2025 | |
| Karyopharm Therapeutics INC. | $31.20 | 2020 | |
| Puma Biotechnology, INC. | $29.60 | 2024 | |
| Foundation Medicine, INC. | $27.36 | 2019 | |
| Blueprint Medicines Corporation | $24.62 | 2023 | Ayvakit |
| Array Biopharma INC | $23.43 | 2022 | |
| Coherus Oncology, INC. | $22.32 | 2023 | |
| Cti Biopharma Corp. | $20.67 | 2022 | |
| Genmab U.S., INC. | $20.09 | 2024 | Epkinly |
| Apellis Pharmaceuticals, INC. | $19.37 | 2024 | Empaveli |
| Deciphera Pharmaceuticals INC. | $19.12 | 2024 | Qinlock, Tgct |
| Recordati_rare_diseases_inc. | $16.02 | 2024 | Sylvant |
| Immunogen, INC. | $16.00 | 2024 | Elahere |
| Novocure INC. | $15.18 | 2025 | Optune Lua (Novottf-200t) |
| Mirati Therapeutics, INC. | $15.16 | 2023 | Krazati |
| Tesaro, INC. | $14.48 | 2019 | |
| Myovant Sciences INC. | $12.58 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geetha Varma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.